Circulating CD56bright NK cells inversely correlate with survival of melanoma patients.

Abstract	The roles of NK cells in human melanoma remain only partially understood. We characterized NK cells from peripheral blood ex vivo by flow cytometry obtained from late stage (III/IV) melanoma patients. Interestingly, we found that the abundance of CD56bright NK cells negatively correlate with overall patient survival, together with distant metastases, in a multivariate cox regression analysis. The patients' CD56bright NK cells showed upregulation of CD11a, CD38 and CD95 as compared to healthy controls, pointing to an activated phenotype as well as a possible immune regulatory role in melanoma patients. After stimulation in vitro, CD56bright NK cells produced less TNFα and GMCSF in patients than controls. Furthermore, IFNγ production by the CD56bright NK cells correlated inversely with overall survival. Our results highlight that abundance and function of CD56bright NK cells are associated with melanoma patient survival, emphasizing the potential of NK cell subsets for biomarker discovery and future therapeutic targeting.
Authors	Kaat de Jonge, Anna Ebering, Sina Nassiri, Hélène Maby-El Hajjami, Hajer Ouertatani-Sakouhi, Petra Baumgaertner, Daniel E Speiser
Journal	Scientific reports (Sci Rep) Vol. 9 Issue 1 Pg. 4487 (03 14 2019) ISSN: 2045-2322 [Electronic] England
PMID	30872676 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References	Biomarkers, Tumor CD56 Antigen CSF2 protein, human IFNG protein, human Interferon-gamma Granulocyte-Macrophage Colony-Stimulating Factor
Topics	Biomarkers, Tumor (blood) CD56 Antigen (blood) Case-Control Studies Female Flow Cytometry Granulocyte-Macrophage Colony-Stimulating Factor (metabolism) Humans Interferon-gamma (metabolism) Killer Cells, Natural (immunology) Male Melanoma (immunology, mortality, pathology) Neoplasm Metastasis Neoplasm Staging Phenotype Regression Analysis Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!